|Bid||25.26 x 2200|
|Ask||26.94 x 900|
|Day's Range||24.00 - 26.01|
|52 Week Range||8.61 - 36.10|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.00|
“We are excited to welcome Tom to our Board of Directors,” stated Heath Lukatch, Ph.D., Chairman of Satsuma’s Board of Directors. "With his extensive operational and financial expertise in clinical-stage biopharmaceutical companies, as well as his capital markets experience, Tom brings a relevant and valuable perspective to Satsuma as we advance through Phase 3 development and prepare to commercialize our lead asset, STS101, being developed for the acute treatment of migraine.”
Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT) Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception The Efficacy of.
SOUTH SAN FRANCISCO, Calif., June 01, 2020 -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported completion of enrollment.
SOUTH SAN FRANCISCO, Calif., May 27, 2020 -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins,.
Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations.
“Despite challenges posed by the COVID-19 pandemic, the Satsuma team has continued to advance the development of STS101 with no significant changes to program timelines,” commented John Kollins, Satsuma’s President and Chief Executive Officer. Satsuma continues to randomize and treat patients in the ongoing EMERGE trial and does not currently anticipate delays in study execution due to the COVID-19 pandemic. Consistent with prior guidance, Satsuma expects to report topline data for the EMERGE trial in the second half of 2020.
The event will feature presentations by headache medicine specialists Jessica Ailani, MD, from MedStar Georgetown Headache Center, and Alan Rapoport, MD, from The David Geffen School of Medicine at UCLA, addressing the current treatment landscape for the acute treatment of migraine, unmet needs, and potential roles for Satsuma’s product candidate, STS101. As well, Satsuma's Chief Medical Officer, Detlef Albrecht, MD, will review the design of the ongoing STS101 EMERGE™ Phase 3 pivotal efficacy and safety trial.
On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine Company well-capitalized with.
As Satsuma’s Chief Commercial Officer, Mr. Janosky will be responsible for all commercial activities, as well as leading business development and corporate partnering. Mr. Janosky brings to Satsuma a wealth of commercial experience within the biopharmaceutical industry spanning more than twenty-five years, including business development, marketing, sales, brand development, new product planning, and product launch leadership roles in orphan, specialty, and primary care markets.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins,.
Satsuma Pharmaceuticals, Inc. (STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results detailing pharmacokinetics (PK), tolerability, and safety with its lead product candidate, STS101 (DHE (or dihydroergotamine) nasal powder for the acute treatment of migraine), have been published online in the official peer-reviewed journal of the American Headache Society, Headache, The Journal of Head and Face Pain. The publication reports results from a Phase 1, open-label, 2-part, active-controlled, 3-period crossover study sponsored by Satsuma and designed to investigate and compare the safety and PK of STS101, DHE liquid nasal spray (Migranal®), and intramuscular (IM) DHE injection in healthy subjects.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins,.
Completed upsized initial public offering of $90.8 million in gross proceeds Dosed first patient in Phase 3 EMERGE™ efficacy trial of STS101 for the acute treatment of migraine.